---
layout: post
title: "Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:35:29 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-02103
original_published: 2023-02-01 00:00:00 +0000
significance: 8.00
---

# Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** February 01, 2023 00:00 UTC
**Document Number:** 2023-02103

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment." The purpose of this draft guidance is to assist sponsors in the clinical development of drugs for the treatment of early Lyme disease as manifested by erythema migrans (EM).

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/02/01/2023-02103/early-lyme-disease-as-manifested-by-erythema-migrans-developing-drugs-for-treatment-draft-guidance)
- API: https://www.federalregister.gov/api/v1/documents/2023-02103

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
